Promising Preclinical Data Support TPC-026 as a Novel Chronic Therapy for Metabolic Disorders Including Obesity

Press release Copenhagen, Denmark, 28 January 2026. TETRAPHARM, a Copenhagen-based biopharmaceutical company focused on neuroscience, psychiatry, and metabolic disorders, today announced promising preclinical data for TPC-026, a novel investigational compound being developed for the chronic treatment and long-term management of multiple metabolic disorders, including obesity. The preclinical findings support TPC-026 as a differentiated therapeutic candidate, designed to address underlying disease mechanisms, rather than symptoms alone, in line with TETRAPHARM’s core philosophy of